Physician profile
Faizul Haque
NPI 1609952597
$21,884.32
in general payments reported to CMS, 2019-2025
39 companies · $3,747 in 2025
The $3,747 reported for 2025 was more than what 90% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,168 · 2020: $173 · 2021: $84.26 · 2022: $8,350 · 2023: $1,711 · 2024: $2,651 · 2025: $3,747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,421 · Travel and Lodging: $1,589 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,421.18 |
| Travel and Lodging | $1,588.91 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $16,120.06 | 2019-2025 | Amplatzer Amulet, Triclip, Cardiomems |
| Boston Scientific Corporation | $462.78 | 2022-2025 | Lux-Dx Insertable Cardiac Monitor, Watchman Flx, Bodyguardian |
| E.R. Squibb & Sons, L.L.C. | $446.06 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $394.15 | 2020-2025 | Wainua, Brilinta, Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $381.25 | 2023-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $317.65 | 2023-2025 | |
| Abiomed | $311.62 | 2019-2025 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.19 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $227.47 | 2023-2024 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $211.64 | 2021-2024 | Xarelto |
| Cvrx, INC. | $206.36 | 2024-2025 | Barostim Neo System |
| Heartflow, INC. | $199.91 | 2020-2025 | Ffrct |
| Esperion Therapeutics, INC. | $191.15 | 2023-2025 | Nexletol |
| Amgen INC. | $187.18 | 2021-2025 | Repatha, Repatha |
| Impulse Dynamics (USA) INC. | $186.20 | 2023 | Optimizer |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $168.63 | 2024 | |
| Siemens Medical Solutions USA, INC. | $136.87 | 2024-2025 | Artis Icono Biplane |
| Shockwave Medical, INC | $127.64 | 2022-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Biotronik INC. | $113.67 | 2023-2024 | Biomonitor, Edora 8 Dr-T |
| Baxter Healthcare | $112.55 | 2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Philips North America LLC | $111.68 | 2024-2025 | Igt Devices Systems Undivided, Mcot, (5044) Mcot |
| Kiniksa Pharmaceuticals International, Plc | $111.22 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $111.09 | 2023-2024 | Verquvo |
| Alnylam Pharmaceuticals INC. | $110.19 | 2024-2025 | Amvuttra |
| Kiniksa Pharmaceuticals, LTD. | $104.47 | 2023 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $92.39 | 2023-2025 | |
| Cardiva Medical, INC. | $77.04 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Inspire Medical Systems, INC. | $61.30 | 2023-2024 | Inspire |
| Medtronic, INC. | $54.44 | 2025 | Affera Mapping System |
| Glaxosmithkline, LLC. | $49.49 | 2025 | Shingrix |
| Daiichi Sankyo INC. | $49.07 | 2023 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $42.74 | 2024 | Evkeeza |
| Cathworks, INC. | $37.30 | 2020 | |
| Edwards Lifesciences Corporation | $34.35 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Pfizer INC. | $28.77 | 2023-2025 | |
| Penumbra, INC. | $22.74 | 2021 | |
| Atricure, INC. | $20.68 | 2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Scpharmaceuticals INC. | $17.85 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $16.48 | 2023 | Uptravi, Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faizul Haque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.